

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Jun 04, 2021

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/novartis-investigational-checkpoint-inhibitor-tislelizumab-met-primary-endpoint-overall-survival-pivotal-phase-iii-trial-esophageal-cancer-after-systemic-therapy-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-investigational-checkpoint-inhibitor-tislelizumab-met-primary-endpoint-overall-survival-pivotal-phase-iii-trial-esophageal-cancer-after-systemic-therapy-0>